January 31, 2017
Teva launches two asthma products in 2017 to compete with GSK
Teva’s two asthma treatments for patients older than 12 has been approved by the US Food and Drug Administration (FDA).
Pharmaceuticals, Biotechnology and Life Sciences
Category: Approval
January 31, 2017
US Court rules in Mylan’s favor, another decision against Teva
Israel’s largest drugmaker, Teva, has came up short yet again against a US courts regarding patent infringement cases.
January 31, 2017
US Court rules in Mylan’s favor, another decision against Teva
Israel’s largest drugmaker, Teva, has came up short yet again against a US courts regarding patent infringement cases.
January 31, 2017
European Commission OK’s Novartis’s tuberous sclerosis complex drug
European Commission has approved Novartis’s Votubia (everolimus) dispersible tablets as an adjunctive treatment for patients aged two years and older whose…
January 31, 2017
TiGenix kicks off Sepcell trial to test new pneumonia treatment
TiGenix has enrolled the first patient and treated in a Phase Ib/IIa clinical trial for Cx611 (SEPCELL) in the treatment of severe sepsis in community-acquired pneumonia (CAP).
January 30, 2017
Novo Nordisk invests £115 in new type 2 diabetes research with Oxford
Novo Nordisk and University of Oxford have expanded their partnership on researching type 2 diabetes, and will open a new research centre in Oxford.
January 30, 2017
Short: Shield’s secretary officially resigns
Shield Therapeutics has appointed Capita Registrars Limited as company secretary, after Richard Jones has officially resigned.
January 30, 2017
CHMP recommends Pfizer’s rheumatoid arthritis drug for European approval
The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended Pfizer’s Xeljanz (tofacitinib citrate)…
January 30, 2017
Another USA laswusit against Teva, Aralez charges for 4 patent infringements
Aralez Pharmaceuticals will press charges against Teva in the USA for infringing four patents.
January 30, 2017
Drugmaker Novo Nordisk bets $145 million on post-Brexit UK science
Novo Nordisk, the world’s top maker of diabetes drugs, is investing 115 million pounds ($145 million) in a new research center in Britain, undeterred by Brexit.